Kubota Vision

Kubota Vision Inc., a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), is dedicated to transforming innovation into a diverse portfolio of pharmaceuticals and devices to protect and restore the vision of millions of people worldwide. The Kubota Pharmaceutical Group’s development pipeline includes drug candidates for the treatment of diabetic retinopathy and Stargardt disease, as well as a gene therapy based on optogenetics for treating retinitis pigmentosa. The company is also developing a handheld OCT device for patient self-monitoring of neovascular retinal diseases, along with a wearable device for myopia control.